Marker Therapeutics, Inc. (NASDAQ:MRKR) Stock Short Interest Falls 35.4%

Marker Therapeutics, Inc. (NASDAQ:MRKR) saw a significant decrease in short interest in the month of October. As of October 15th, there was short interest totaling 109,110 shares, a decrease of 35.4% from the September 30th total of 168,895 shares. Approximately 0.7% of the company’s shares are short sold. Based on an average daily volume of 97,400 shares, the short-interest ratio is presently 1.1 days.

Analyst Ratings Changes

Several brokerages have recently issued reports on MRKR. Weiss Ratings raised shares of Marker Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 19th. HC Wainwright restated a “buy” rating on shares of Marker Therapeutics in a report on Friday, August 21st. Finally, Zacks Research raised shares of Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.00.

Marker Therapeutics Stock Up 2.8%

NASDAQ MRKR traded up $0.02 on Tuesday, hitting $0.93. 14,751 shares of the stock were exchanged, compared to its average volume of 152,755. Marker Therapeutics has a fifty-two week low of $0.84 and a fifty-two week high of $2.46. The company has a market cap of $15.44 million, a PE ratio of -2.28 and a beta of 1.53. The company has a 50-day moving average price of $1.14 and a 200-day moving average price of $1.37.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.16. As a group, equities research analysts predict that Marker Therapeutics will post -0.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Marker Therapeutics

A hedge fund recently raised its stake in Marker Therapeutics stock. Renaissance Technologies LLC raised its holdings in Marker Therapeutics, Inc. (NASDAQ:MRKR) by 41.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 175,294 shares of the company’s stock after buying an additional 51,644 shares during the period. Renaissance Technologies LLC owned about 1.05% of Marker Therapeutics worth $228,000 as of its most recent SEC filing. Institutional investors and hedge funds own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. The company’s platform is designed to produce multi-antigen-targeted T cells, which recognize several tumor-associated antigens rather than a single target. Marker Therapeutics has been developing these therapies for use in patients with hematologic malignancies and solid tumors.

The company’s investigational pipeline has included MT-601, an autologous multiTAA-specific T-cell therapy being evaluated for certain solid tumors, and MT-401, a related therapy developed for acute myeloid leukemia.